Figure 3From: A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma Serum concentration versus time profile of multiple doses of CAT-354 at doses of (A) 1 mg/kg, (B) 5 mg/kg and (C) 10 mg/kg administered at 28-day intervals by intravenous infusion.Back to article page